Serum Metabolomics Study of Gliclazide-Modified-Release-Treated Type 2 Diabetes Mellitus Patients Using a Gas Chromatography-Mass Spectrometry Method
文献类型：期刊论文
| 作者 | Lu, Xin1,2; Jia, Weiping3; Xu, Guowang1,2; Zhou, Yang1,2; Hu, Cheng3,4; Zhao, Xinjie1,2; Luo, Ping1,2; Lu, Jingyi3; Li, Qing3; Chen, Miao3 |
| 刊名 | JOURNAL OF PROTEOME RESEARCH
 |
| 出版日期 | 2018-04-01 |
| 卷号 | 17期号:4页码:1575-1585 |
| 关键词 | Metabolomics Gliclazide Modified Release Sulfonylureas Type 2 Diabetes Mellitus Gas Chromatography-mass Spectrometry Biomarker |
| ISSN号 | 1535-3893 |
| DOI | 10.1021/acs.jproteome.7b00866 |
| 文献子类 | Article |
| 英文摘要 | Sulfonylureas are one of the commonly used drugs in type 2 diabetes mellitus (T2DM) but with considerable incidence of monotherapy failure. However, the mechanism of patients' drug response is unclear, and suitability evaluation biomarkers are in urgent need for precision medicine. In this study, a pseudotargeted gas chromatography-mass spectrometry method was employed to investigate the serum metabolic profiling of 66 significant responders and 24 nonsignificant responders at baseline and 16 weeks after gliclazide modified-release (MR) monotherapy. Clinical improvements in blood glucose level and insulin sensitivity were closely associated with the alterations of TCA cycle, ketone body metabolism, lipid oxidation, branched-chain amino acid catabolism, and gut flora metabolism. The different baseline metabolic profiling observed in the two groups implied that patients with lower dyslipidemia level may be more suitable for sulfonylurea therapy. The biomarker panel consisting of HbA1C, 5,8,11,14,17-eicosapentaenoic acid, methyl 8,11,14-eicosatrienoate, and methyl hexadecanoate shows a very good prediction ability for the suitability of glidazide treatment, and it may be meaningful in personalized medicine of T2DM patients by sulfonylurea therapy. |
| WOS关键词 | INSULIN-RESISTANCE ; HEPATOCELLULAR-CARCINOMA ; METABOLITE BIOMARKER ; GLUCOSE-HOMEOSTASIS ; SKELETAL-MUSCLE ; SULFONYLUREA ; EFFICACY ; TAURINE ; ALPHA ; BETA |
| WOS研究方向 | Biochemistry & Molecular Biology |
| 语种 | 英语 |
| WOS记录号 | WOS:000429886600021 |
| 出版者 | AMER CHEMICAL SOC |
| 源URL | [http://cas-ir.dicp.ac.cn/handle/321008/169160]  |
| 专题 | 大连化学物理研究所_中国科学院大连化学物理研究所 |
| 通讯作者 | Lu, Xin; Jia, Weiping; Xu, Guowang |
| 作者单位 | 1.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 2.Chinese Acad Sci, Dalian Inst Chem Phys, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China 3.Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai Diabet Inst,Shanghai Clin Ctr Diabet, Dept Endocrinol & Metab,Shanghai Key Lab Diabet M, Shanghai 200233, Peoples R China 4.Southern Med Univ, Fengxian Cent Hosp Affiliated, Inst Metab Dis, 6600 Nanfeng Rd, Shanghai 201499, Peoples R China |
| 推荐引用方式 GB/T 7714 | Lu, Xin,Jia, Weiping,Xu, Guowang,et al. Serum Metabolomics Study of Gliclazide-Modified-Release-Treated Type 2 Diabetes Mellitus Patients Using a Gas Chromatography-Mass Spectrometry Method[J]. JOURNAL OF PROTEOME RESEARCH,2018,17(4):1575-1585. |
| APA | Lu, Xin.,Jia, Weiping.,Xu, Guowang.,Zhou, Yang.,Hu, Cheng.,...&Kong, Hongwei.(2018).Serum Metabolomics Study of Gliclazide-Modified-Release-Treated Type 2 Diabetes Mellitus Patients Using a Gas Chromatography-Mass Spectrometry Method.JOURNAL OF PROTEOME RESEARCH,17(4),1575-1585. |
| MLA | Lu, Xin,et al."Serum Metabolomics Study of Gliclazide-Modified-Release-Treated Type 2 Diabetes Mellitus Patients Using a Gas Chromatography-Mass Spectrometry Method".JOURNAL OF PROTEOME RESEARCH 17.4(2018):1575-1585. |
入库方式： OAI收割
来源：大连化学物理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。